Recovery-promoting drugs after stroke: a systematic review
and/or levodopa coupled with physiotherapy on functional
and motor recovery after stroke – a randomized, double-
blind, placebo-controlled trial. Acta Neurologica Scandi-
navica 2011; 123: 266–273.
30. Mikami K, Jorge RE, Adams HP, Davis PH, Leira EC, Jang
MJ, et al. Effect of antidepressants on the course of disa-
bility following stroke. Am J Geriatr Psychiatry 2011; 19:
1007–1015.
31. Urfer R, Moebius HJ, Skoloudik D, Santamarina E, Sato
W, Mita S, et al. Phase II Trial of the sigma-1 receptor
agonist cutamesine (SA4503) for recovery enhancement
after acute ischemic stroke. Stroke 2014; 45: 3304–3310.
32. Amiri-Nikpour MR, Nazarbaghi S, Ahmadi-Salmasi B,
Mokari T, Tahamtan U, Rezaei Y. Cerebrolysin effects
on neurological outcomes and cerebral blood flow in
acute ischemic stroke. Neuropsychiatr Dis Treat 2014;
10: 2299–2306.
33. Chang WH, Park CH, Kim DY, Shin YI, Ko MH, Lee A, et al.
Cerebrolysin combined with rehabilitation promotes motor
recovery in patients with severe motor impairment after
stroke. BMC Neurol 2016; 16: 31.
34. Heiss W-D, Brainin M, Bornstein NM, Tuomilehto J, Hong Z.
Cerebrolysin in patients with acute ischemic stroke in asia
results of a double-blind, placebo-controlled randomized
trial. Stroke 2012; 43: 630–636.
35. Lang W, Stadler CH, Poljakovic Z, Fleet D, Lyse Study
Group. A prospective, randomized, placebo-controlled,
double-blind trial about safety and efficacy of combined
treatment with alteplase (rt-PA) and cerebrolysin in
acute ischaemic hemispheric stroke. Int J Stroke 2013;
8: 95–104.
36. Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Po-
pescu CD, Vester JC, et al. Cerebrolysin and Recovery
After Stroke (CARS): a randomized, placebo-controlled,
double-blind, multicenter trial. Stroke 2016; 47: 151–159.
37. Gladstone DJ, Danells CJ, Armesto A, McIlroy WE, Staines
WR, Graham SJ, et al. Physiotherapy coupled with dextro-
amphetamine for rehabilitation after hemiparetic stroke: a
randomized, double-blind, placebo-controlled trial. Stroke
2006; 37: 179–185.
38. Platz T, Kim IH, Engel U, Pinkowski C, Eickhof C, Kutzner
M. Amphetamine fails to facilitate motor performance and
to enhance motor recovery among stroke patients with
mild arm paresis: interim analysis and termination of a
double blind, randomised, placebo-controlled trial. Restor
Neurol Neurosci 2005; 23: 271–280.
39. Schuster C, Maunz G, Lutz K, Kischka U, Sturzenegger
R, Ettlin T. Dexamphetamine improves upper extremity
outcome during rehabilitation after stroke: a pilot ran-
domized controlled trial. Neurorehabil Neural Repair 2011;
25: 749–755.
40. Sprigg N, Willmot MR, Gray LJ, Sunderland A, Pomeroy V,
Walker M, et al. Amphetamine increases blood pressure
and heart rate but has no effect on motor recovery or ce-
rebral haemodynamics in ischaemic stroke: a randomized
controlled trial (ISRCTN 36285333). J Hum Hypertens
2007; 21: 616–624.
41. Treig T, Werner C, Sachse M, Hesse S. No benefit from D-
amphetamine when added to physiotherapy after stroke: a
randomized, placebo-controlled study. Clin Rehabil 2003;
17: 590–599.
42. Walker-Batson D, Smith P, Curtis S, Unwin H, Greenlee
R. Amphetamine paired with physical therapy accelerates
motor recovery after stroke. Further evidence. Stroke
1995; 26: 2254–2259.
43. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of le-
vodopa in combination with physiotherapy on functional
motor recovery after stroke: a prospective, randomised,
double-blind study. Lancet 2001; 358: 787–790.
44. Chen CLH, Young SHY, Gan HH, Singh R, Lao AY, Baroque
AC, et al. Chinese medicine neuroaid efficacy on stroke
recovery a double-blind, placebo-controlled, randomized
study. Stroke 2013; 44: 2093–2100.
329
45. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy
C, et al. Fluoxetine for motor recovery after acute ischae-
mic stroke (FLAME): a randomised placebo-controlled trial.
Lancet Neurol 2011; 10: 123–130. Erratum in: Lancet
Neurol 2011; 10: 205.
46. Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney
LA. Randomized, placebo-controlled, double-blind study of
ropinirole in chronic stroke. Stroke 2009; 40: 3034–3038.
47. Bartolo M, Zucchella C, Capone A, Sandrini G, Pierelli F.
An explorative study regarding the effect of L-deprenyl on
cognitive and functional recovery in patients after stroke.
J Neurol Sci 2015; 349: 117–123.
48. Bavarsad Shahripour R, Shamsaei G, Pakdaman H, Majdi-
nasab N, Nejad EM, Sajedi SA, et al. The effect of Neuro-
AiD? (MLC601) on cerebral blood flow velocity in subjects’
post brain infarct in the middle cerebral artery territory.
Eur J Intern Med 2011; 22: 509–513.
49. Bochner F, Eadie MJ, Tyrer JH. Use of an ergot preparation
(hydergine) in the convalescent phase of stroke. J Am
Geriatr Soc 1973; 21: 10–17.
50. Cramer SC, Enney LA, Russell CK, Simeoni M, Thompson
TR. Proof-of-concept randomized trial of the monoclonal
antibody GSK249320 versus placebo in stroke patients.
Stroke 2017; 48: 692–698.
51. Kong KH, Wee SK, Ng CY, Chua K, Chan KF, Venketasub-
ramanian N, et al. A double-blind, placebo-controlled,
randomized phase II pilot study to investigate the poten-
tial efficacy of the traditional chinese medicine Neuroaid
(MLC 601) in enhancing recovery after stroke (TIERS).
Cerebrovasc Dis 2009; 28: 514–521.
52. Li S, Long J, Ma Z, Xu Z, Li J, Zhang Z. Assessment of
the therapeutic activity of a combination of almitrine and
raubasine on functional rehabilitation following ischaemic
stroke. Curr Med Res Opin 2004; 20: 409–415.
53. Mohammadianinejad SE, Majdinasab N, Sajedi SA, Ab-
dollahi F, Moqaddam MM, Sadr F. The effect of lithium
in post-stroke motor recovery: a double-blind, placebo-
controlled, randomized clinical trial. Clin Neuropharmacol
2014; 37: 73–78.
54. Oskouei DS, Rikhtegar R, Hashemilar M, Sadeghi-Bazar-
gani H, Sharifi-Bonab M, Sadeghi-Hokmabadi E, et al. The
effect of Ginkgo biloba on functional outcome of patients
with acute ischemic stroke: a double-blind, placebo-
controlled, randomized clinical trial. J Stroke Cerebrovasc
Dis 2013; 22: e557–e563.
55. Ringelstein EB, Thijs V, Norrving B, Chamorro A, Aichner
F, Grond M, et al. Granulocyte colony-stimulating factor in
patients with acute ischemic stroke results of the AX200
for ischemic stroke trial. Stroke 2013; 44: 2681–2687.
56. Sivenius J, Sarasoja T, Aaltonen H, Heinonen E, Kilkku O,
Reinikainen K. Selegiline treatment facilitates recovery af-
ter stroke. Neurorehabil Neural Repair 2001; 15: 183–190.
57. Venketasubramanian N, Young S, Tay S, Umapathi T,
Lao A, Gan H, et al. CHInese Medicine NeuroAiD Efficacy
on Stroke Recovery – Extension Study (CHIMES-E): a
Multicenter Study of Long-Term Efficacy. Cerebrovasc Dis
2015; 39: 309–318.
58. Ward A, Carrico C, Powell E, Westgate PM, Nichols L,
Fleischer A, et al. Safety and improvement of movement
function after stroke with atomoxetine: a pilot randomized
trial. Restor Neurol Neurosci 2017; 35: 1–10.
59. Yu M, Sun ZJ, Li LT, Ge HY, Song CQ, Wang AJ. The be-
neficial effects of the herbal medicine Di-huang-yin-zi
(DHYZ) on patients with ischemic stroke: a randomized,
placebo controlled clinical study. Complement Ther Med
2015; 23: 591–597.
60. Acler M, Robol E, Fiaschi A, Manganotti P. A double blind
placebo RCT to investigate the effects of serotonergic
modulation on brain excitability and motor recovery in
stroke patients. J Neurol 2009; 256: 1152–1158.
61. Cramer SC, Hill MD, Regenesis-Led Investigators. Human
choriogonadotropin and epoetin alfa in acute ischemic
stroke patients (REGENESIS- LED trial). Int J Stroke
J Rehabil Med 51, 2019